Study of Fourier Transform Infrared Spectroscopy FTIRS to Prevent Spread of ESBL-Producing Bacteria in Intensive Care Units

What this Trial Is About

Multidrug resistant enterobacterales MDR-E pose a significant risk to patients in intensive care units ICUs. This research aims to evaluate the use of Fourier Transform Infrared Spectroscopy FTIRS typing to detect and prevent the spread of extended spectrum beta-lactamase producing enterobacteriaceae ESBL-E in ICUs. FTIRS offers a faster and simpler alternative to whole genome sequencing WGS, which is costly and less accessible. The study has two main phases. Initially, the frequency of ESBL-E cross transmission will be assessed using WGS on the first ESBL-E isolate from carrier patients in each center. In the second phase, weekly FTIRS typing results of ESBL-E isolates will be shared with participating centers to assess its impact on preventing spread. Standard care practices to control MDR-E spread will continue throughout. Participants are adult ICU patients who carry ESBL-E. Researchers will monitor the rate of ESBL-E cross transmission before and after sharing FTIRS results, using WGS to confirm transmissions. Outcome measures include sensitivity, specificity, and predictive values of FTIRS compared to WGS. The study will follow participants up to 24 months, with regular bacterial sampling and data review to evaluate the effectiveness of FTIRS in real-world ICU settings.

Impact of Fourier Transform Infrared Spectroscopy (FTIRS) in ICUs